Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia
暂无分享,去创建一个
E. Shpall | U. Popat | M. Qazilbash | L. Worth | R. Champlin | S. Giralt | P. Anderlini | G. Okoroji | S. Acholonu | R. Bassett
[1] H. Einsele,et al. Outcome of treatment of Epstein–Barr virus‐related post‐transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases , 2009, Transplant infectious disease : an official journal of the Transplantation Society.
[2] M. Aljurf,et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen , 2009, Haematologica.
[3] F. Locatelli,et al. Fludarabine, Cyclophosphamide with or without Low Dose TBI for Alternative Donor Transplants in Acquired Aplastic Anemia (SAA): A Report From the EBMT-SAA Working Party , 2009 .
[4] M. Aljurf,et al. Hematopoietic Recovery and Overall Survival after HLA-Matched Sibling Transplants for Older Patients with Severe Aplastic Anemia (SAA). , 2008 .
[5] A. Ibatici,et al. Rituximab Prophylaxis of EBV Reactivation after Alternative Donor Transplants Following Anti-Thymocyte Globulin-Based Conditioning Regimens. , 2008 .
[6] R. Storb,et al. Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Severe Aplastic Anemia (SAA) above the Age of 40 Years. , 2006 .
[7] R. Collins,et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. , 2006, Blood.
[8] P. Bruzzi,et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] H. Deeg,et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] N. Geller,et al. Overcoming graft rejection in heavily transfused and allo‐immunised patients with bone marrow failure syndromes using fludarabine‐based haematopoietic cell transplantation , 2006, British journal of haematology.
[11] F. Locatelli,et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party , 2005, Bone Marrow Transplantation.
[12] A. Ibatici,et al. Rituximab Prophylaxis of EBV Reactivation after Unrelated Donor Transplants Using Anti-Thymocyte Globulin in the Conditioning Regimen. , 2005 .
[13] Y. Lee,et al. Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia , 2005, Bone Marrow Transplantation.
[14] H. Shin,et al. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia , 2004, Bone Marrow Transplantation.
[15] R. Collins,et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] F. Benvenuto,et al. Thiotepa Cyclophosphamide Followed by Granulocyte Colony-Stimulating Factor Mobilized Allogeneic Peripheral Blood Cells in Adults With Advanced Leukemia , 1996 .
[17] A. Bacigalupo,et al. Aplastic anemia: pathogenesis and treatment. , 1987, Onkologie.